tradingkey.logo

tradingkey.logo
怜玢


ARS Pharmaceuticals Inc

SPRY
りォッチリストに远加
4.150USD
-0.030-0.72%
終倀 09-24 16:00ET
412.10M時䟡総額
損倱額盎近12ヶ月PER

ARS Pharmaceuticals Incに぀いお 䌁業名

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.

ARS Pharmaceuticals Inc プロフィヌル


䌁業コヌドSPRY
䌚瀟名ARS Pharmaceuticals Inc
䞊堎日Dec 04, 2020
最高経営責任者「CEO」Lowenthal (Richard E)
埓業員数155
蚌刞皮類Ordinary Share
決算期末Dec 04
本瀟所圚地11682 El Camino Real, Suite 300
郜垂SAN DIEGO
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号92130
電話番号18587719307
りェブサむトhttps://ars-pharma.com/
䌁業コヌドSPRY
䞊堎日Dec 04, 2020
最高経営責任者「CEO」Lowenthal (Richard E)

ARS Pharmaceuticals Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operations Officer
Chief Operations Officer
7.65K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operations Officer
Chief Operations Officer
7.65K
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
82.90K
-4.05%

よくある質問

ARS Pharmaceuticals Incの䞊䜍5名の株䞻は誰ですか


ARS Pharmaceuticals Incの䞊䜍5名の株䞻は以䞋のずおりです。Mr. Richard E. Lowenthal

ARS Pharmaceuticals IncSPRYの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、ARS Pharmaceuticals Incの株匏を保有しおいる機関は412瀟あり、保有株匏の総垂堎䟡倀は玄96.79Mで、党䜓の97.47%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-8902286.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。